Traders Purchase Large Volume of Call Options on SELLAS Life Sciences Group (NASDAQ:SLS)

SELLAS Life Sciences Group logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Call-option activity surged: Investors bought 261,202 SLS call options, about 522% above the average volume.
  • The stock jumped sharply: Shares rose 156.4% to $19.15 in Tuesday trading, on volume far above the company’s average.
  • Analyst views remain mixed: MarketBeat’s consensus rating was Hold, with a $10 target price; SELLAS also plans FDA discussions about its regulatory path and is preparing for a possible BLA submission in the first half of 2027.
  • MarketBeat previews top five stocks to own in December.

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) was the recipient of unusually large options trading activity on Tuesday. Stock investors bought 261,202 call options on the company. This represents an increase of approximately 522% compared to the average volume of 42,008 call options.

SELLAS Life Sciences Group Trading Up 156.4%

SLS stock traded up $11.68 during mid-day trading on Tuesday, hitting $19.15. 118,919,137 shares of the company were exchanged, compared to its average volume of 8,361,787. The firm has a fifty day simple moving average of $10.90 and a 200 day simple moving average of $8.79. The company has a market capitalization of $3.87 billion, a PE ratio of -95.75 and a beta of 2.73. SELLAS Life Sciences Group has a twelve month low of $1.39 and a twelve month high of $24.89.

SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) last issued its earnings results on Thursday, November 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.05).

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. Weiss Ratings restated a "sell (d-)" rating on shares of SELLAS Life Sciences Group in a research note on Thursday, October 15th. Alliance Global Partners reissued a "buy" rating on shares of SELLAS Life Sciences Group in a report on Wednesday, August 12th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Hold" and a consensus target price of $10.00.

Get Our Latest Stock Analysis on SELLAS Life Sciences Group

More SELLAS Life Sciences Group News

Here's some of the latest news about SLS:

  • Positive Sentiment: SELLAS plans to meet with the FDA to discuss the regulatory path, including a possible accelerated filing strategy, and is preparing for a Biologics License Application submission in the first half of 2027. GPS was generally well tolerated, with no new safety signals reported.
  • Positive Sentiment: Options trading was unusually active, with investors buying 261,202 call options—about 522% above the average volume. This suggests heightened bullish speculation, but options activity does not guarantee future performance.
  • Negative Sentiment: The results are topline data; comprehensive analyses of secondary endpoints are still underway. FDA agreement on the data, filing strategy, timing, and eventual approval is not assured. The trial studied a specific high-risk AML population, so the findings may not apply broadly.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Dagco Inc. increased its holdings in shares of SELLAS Life Sciences Group by 8.4% in the 3rd quarter. Dagco Inc. now owns 1,336,449 shares of the company's stock valued at $16,452,000 after acquiring an additional 104,016 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in SELLAS Life Sciences Group by 86.0% in the third quarter. Goldman Sachs Group Inc. now owns 1,088,136 shares of the company's stock worth $13,395,000 after purchasing an additional 503,101 shares during the period. Bank of America Corp DE boosted its holdings in SELLAS Life Sciences Group by 535.7% in the first quarter. Bank of America Corp DE now owns 641,683 shares of the company's stock worth $2,714,000 after purchasing an additional 540,748 shares during the period. Wellington Management Group LLP boosted its holdings in SELLAS Life Sciences Group by 73.2% in the second quarter. Wellington Management Group LLP now owns 597,309 shares of the company's stock worth $8,816,000 after purchasing an additional 252,531 shares during the period. Finally, Bank of New York Mellon Corp bought a new stake in SELLAS Life Sciences Group during the second quarter valued at $7,823,000. Institutional investors own 17.38% of the company's stock.

About SELLAS Life Sciences Group

(Get Free Report)

SELLAS Life Sciences Group is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. Its research centers on immunotherapies and other therapies intended to address hematologic malignancies and solid tumors. The company does not have an established portfolio of marketed products; its work is focused on clinical development. Its pipeline includes galinpepimut-S (GPS), an immunotherapy designed to target the Wilms' tumor 1 (WT1) protein, which is found in several types of cancer.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in SELLAS Life Sciences Group Right Now?

Before you consider SELLAS Life Sciences Group, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SELLAS Life Sciences Group wasn't on the list.

While SELLAS Life Sciences Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines